首页> 外文期刊>Trials >Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT)
【24h】

Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT)

机译:给予牛磺酸替罗罗定柠檬酸盐锁定溶液预防成人中性粒细胞减少性血液病患者中心静脉导管感染:一项随机,双盲,安慰剂对照试验(TAURCAT)

获取原文
获取外文期刊封面目录资料

摘要

Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic haematological patients. This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia (>?7?days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC removal, adverse events, and 30-day case-fatality rate. The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may significantly impair patient outcome. ISRCTN, ISRCTN47102251 . Registered on 9 September 2015.
机译:导管相关的血流感染(CRBSI)是植入中心静脉导管(CVC)的癌症患者中最常见的并发症之一,并与大量发病率和死亡率相关。 Taurolidine是一种具有广谱抗菌活性的非抗生素药物,已被用作锁定溶液以在某些情况下防止CRBSI。然而,关于其在高危成人嗜中性白血球减少症患者中的用途知之甚少。这项前瞻性随机临床试验旨在测试以下假设:在预防中性粒细胞减少性血液病患者中,牛磺酸牛磺酸柠檬酸盐锁溶液比安慰剂更有效。这项研究是一项前瞻性,多中心,随机,双盲,平行,优势,安慰剂对照试验。预期将出现长期嗜中性白血球减少症(>?7?天)且植入非隧道式CVC的血液系统癌症患者将被随机分配接受锁定技术(研究组)或单独使用肝素预防性牛磺罗定-柠檬酸-肝素溶液(安慰剂组)。主要终点将是CVC集线器的细菌定植。次要终点是CRBSI,CVC去除,不良事件和30天病死率的发生率。锁定技术是一种预防策略,可以抑制细菌在导管接头中的定植,这是腔内导管定植和感染发展的第一步。 Taurolidine是一种无毒剂,不会产生抗生素耐药性,因为它是防腐剂而不是抗生素。在对癌症患者进行的几项试验中,牛磺酸对牛磺酸具有争议性。由于缺乏有关成年和/或高危中性粒细胞减少症患者的数据,研究的导管类型(隧道或端口)以及缺乏有关干预措施的信息(例如溶液的停留时间,时间,和锁定技术的周期性)。如果我们的假设得到了证明,则该研究可以为CRBSI高危人群中这种预防措施的潜在有用性提供重要的可靠证据,这种并发症可能会严重损害患者的预后。 ISRCTN,ISRCTN47102251。 2015年9月9日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号